Initial case: 22 April 2017 [1] Ended: 1 July 2017 [2] | |
Confirmed cases | 5 [3] |
---|---|
Probable cases | 3 [3] |
Deaths | 4 [3] |
On 11 May 2017, the Democratic Republic of the Congo (DRC) was identified by the World Health Organization (WHO) as having one Ebola-related death. [4] [5]
As of 8 June 2017, there were five confirmed cases and three probable cases. Of these, four survived and four died. [6] The affected areas of the DRC are Mabongo (one confirmed), Ngayi (one probable), and Nambwa (four confirmed and two probable) in Likati health zone. [6] According to the WHO, "Modelling suggests the risk of further cases is currently low but not negligible.... As of ... [8 June], 83% of simulated scenarios predict no further cases in the next 30 days." [6]
According to the U.S. Centers for Disease Control and Prevention, "Ebola ... is a rare and deadly disease caused by infection with one of the Ebola virus species. Ebola can cause disease in humans and nonhuman primates (monkeys, gorillas, and chimpanzees)." Ebola was first identified in 1976 near the Ebola River in the DRC. [7] More than 11,300 people died in the 2013 to 2016 Ebola outbreak in West Africa. [8]
According to the WHO's "Global Health Observatory", the DRC's population in 2015 was 77,267,000. [9] On 1 July 2017, DRC Minister of Public Health, Dr Oly Ilunga Kalenga, declared that the country had passed a 42-day period with no new recorded cases, and therefore the outbreak was over. [2] [10] [11] A subsequent outbreak of Ebola was declared by WHO on 8 May 2018, in the northwest Province of Équateur. [12]
The first "situation report" from the WHO on 15 May 2017 listed 19 suspected cases and 3 deaths. [13] The first person to request treatment was a 39-year-old male. [13]
On 16 May, the WHO indicated that there had been 21 suspected cases and 3 deaths. Approximately 400 additional individuals were being monitored in the same region of the DRC. [14] On 17 May, WHO said that the number of individuals being monitored had risen to about 416, [15] while the following day, the number of confirmed and suspected cases had risen to 29. [16] As of 24 May, 520 individuals were reported to be on the contact list to monitor their health status. Of those, 226 had completed 21 days of monitoring. [17] As of 27 May, 30 cases had been reclassified as not Ebola-related. [18]
On 13 May 2017, Doctors Without Borders indicated that they would send a team to the most recently affected area in the DRC. [19]
The GAVI vaccine alliance indicated that 300,000 doses of the experimental Ebola vaccine were available if needed. [1] On 28 May, it was reported that the DRC had authorized use of the vaccine. [20]
As of 8 June 2017, the WHO does not recommend any restrictions of travel and trade in relation to this outbreak. [6] The following nine countries have instituted entry screening at airports and ports of entry: Kenya, Malawi, Nigeria, Rwanda, South Africa, Tanzania, Uganda, Zambia, and Zimbabwe. [6] Rwanda has issued travel advisories to avoid unnecessary travel to the DRC. [6] Kenya and Rwanda have implemented information checking on arrival for passengers with a travel history from or through the DRC. [6] According to the WHO, countries have the right to implement these measures. [6]
On 20 May, the news media reported Rwanda's closure of its border with the DRC for passengers coming from affected areas in the DRC. [17] On 23 May, the WHO confirmed that Rwanda is denying entry to visitors with fever who have been to those areas. [17] Under Article 43 of the International Health Regulations (2005), [21] the WHO considers these actions to be "additional health measures ... that significantly interfere with international traffic". [17] As of 8 June the WHO is attempting to obtain and review Rwanda's public health rationale and relevant scientific information for implementing these measures. [6]
The sub-type Zaire ebolavirus has been confirmed in the current outbreak, [22] from the family Filoviridae. [23] It is a single stranded RNA virus, with a 60-90 percent mortality rate (the highest among the strains). [24]
An unusually high mortality has been reported in the local pig population. An investigation into potential causes is being considered. [17]
The virus took its name from the Ebola River near the village in Zaire (now the DRC) where the first documented outbreak occurred. [25] Multiple documented outbreaks of Ebola virus disease have occurred in the DRC since 1976, [26] with the eleven outbreaks that have occurred summarised in the table below.
Date | Country | Major location | Outbreak information | Source | |||
---|---|---|---|---|---|---|---|
Strain | Cases | Deaths | CFR | ||||
Aug 1976 | Zaire | Yambuku | EBOV | 318 | 280 | 88% | [27] |
Jun 1977 | Zaire | Tandala | EBOV | 1 | 1 | 100% | [28] [29] |
May–Jul 1995 | Zaire | Kikwit | EBOV | 315 | 254 | 81% | [30] |
Aug–Nov 2007 | Democratic Republic of the Congo | Kasai-Occidental | EBOV | 264 | 187 | 71% | [31] |
Dec 2008–Feb 2009 | Democratic Republic of the Congo | Kasai-Occidental | EBOV | 32 | 14 | 45% | [32] |
Jun–Nov 2012 | Democratic Republic of the Congo | Orientale | BDBV | 77 | 36 | 47% | [28] |
Aug–Nov 2014 | Democratic Republic of the Congo | Tshuapa | EBOV | 66 | 49 | 74% | [33] |
May–Jul 2017 | Democratic Republic of the Congo | Likati | EBOV | 8 | 4 | 50% | [34] |
Apr–Jul 2018 | Democratic Republic of the Congo | Équateur Province | EBOV | 54 | 33 | 61% | [35] |
Aug 2018–June 2020 | Democratic Republic of the Congo | Kivu | EBOV | 3,470 | 2,280 | 66% | [36] |
June–Nov 2020 | Democratic Republic of the Congo | Équateur Province | EBOV | 130 | 55 | 42% | [37] |
Feb 2021–May 2021 | Democratic Republic of the Congo | North Kivu | EBOV | 12 | 6 | 50% | [38] |
April 2022 | Democratic Republic of the Congo | Équateur Province | EBOV | 5 | 5 | 100% | [39] [40] |
August 2022 | Democratic Republic of the Congo | North Kivu | EBOV | 1 | 1 | 100% | [41] |
Mpox is an infectious viral disease that can occur in humans and other animals. Symptoms include a rash that forms blisters and then crusts over, fever, and swollen lymph nodes. The illness is usually mild, and most of infected individuals recover within a few weeks without treatment. The time from exposure to the onset of symptoms ranges from five to twenty-one days, and symptoms typically last from two to four weeks. However, cases may be severe, especially in children, pregnant women, or people with suppressed immune systems.
Beni is a city in north eastern Democratic Republic of the Congo, lying immediately west of the Virunga National Park and the Rwenzori Mountains, on the edge of the Ituri Forest.
Ebola, also known as Ebola virus disease (EVD) and Ebola hemorrhagic fever (EHF), is a viral hemorrhagic fever in humans and other primates, caused by ebolaviruses. Symptoms typically start anywhere between two days and three weeks after infection. The first symptoms are usually fever, sore throat, muscle pain, and headaches. These are usually followed by vomiting, diarrhoea, rash and decreased liver and kidney function, at which point some people begin to bleed both internally and externally. It kills between 25% and 90% of those infected – about 50% on average. Death is often due to shock from fluid loss, and typically occurs between six and 16 days after the first symptoms appear. Early treatment of symptoms increases the survival rate considerably compared to late start. An Ebola vaccine was approved by the US FDA in December 2019.
A public health emergency of international concern is a formal declaration by the World Health Organization (WHO) of "an extraordinary event which is determined to constitute a public health risk to other States through the international spread of disease and to potentially require a coordinated international response", formulated when a situation arises that is "serious, sudden, unusual, or unexpected", which "carries implications for public health beyond the affected state's national border" and "may require immediate international action". Under the 2005 International Health Regulations (IHR), states have a legal duty to respond promptly to a PHEIC. The declaration is publicized by an IHR Emergency Committee (EC) of international experts, which was developed following the 2002–2004 SARS outbreak.
Recombinant vesicular stomatitis virus–Zaire Ebola virus (rVSV-ZEBOV), also known as Ebola Zaire vaccine live and sold under the brand name Ervebo, is an Ebola vaccine for adults that prevents Ebola caused by the Zaire ebolavirus. When used in ring vaccination, rVSV-ZEBOV has shown a high level of protection. Around half the people given the vaccine have mild to moderate adverse effects that include headache, fatigue, and muscle pain.
In 2014, an outbreak of Ebola virus disease in the Democratic Republic of the Congo (DRC) occurred. Genome sequencing has shown that this outbreak was not related to the 2014–15 West Africa Ebola virus epidemic, but was of the same EBOV species. It began in August 2014 and was declared over in November of that year, after 42 days without any new cases. This is the 7th outbreak there, three of which occurred during the period of Zaire.
The 2018 Équateur province Ebola outbreak occurred in the north-west of the Democratic Republic of the Congo (DRC) from May to July 2018. It was contained entirely within Équateur province, and was the first time that vaccination with the rVSV-ZEBOV Ebola vaccine had been attempted in the early stages of an Ebola outbreak, with a total of 3,481 people vaccinated. It was the ninth recorded Ebola outbreak in the DRC.
Oly Ilunga Kalenga is a Belgian–Congolese medical doctor who was the Democratic Republic of the Congo's Minister of Public Health from 2016 to 2019. He resigned his post on 22 July 2019, then was arrested on 14 September 2019 for allegedly mismanaging a portion of Congo's $4.3 million in Ebola response money, an allegation that he denies.
Likati is a town in the Aketi Territory of Bas-Uélé Province in the north of the Democratic Republic of the Congo (DRC).
The Kivu Ebola epidemic was an outbreak of Ebola virus disease (EVD) mainly in eastern Democratic Republic of the Congo (DRC), and in other parts of Central Africa, from 2018 to 2020. Between 1 August 2018 and 25 June 2020 it resulted in 3,470 reported cases. The Kivu outbreak also affected Ituri Province, whose first case was confirmed on 13 August 2018. In November 2018, the outbreak became the biggest Ebola outbreak in the DRC's history, and had become the second-largest Ebola outbreak in recorded history worldwide, behind only the 2013–2016 Western Africa epidemic. In June 2019, the virus reached Uganda, having infected a 5-year-old Congolese boy who entered Uganda with his family, but was contained.
Ansuvimab, sold under the brand name Ebanga, is a monoclonal antibody medication for the treatment of Zaire ebolavirus (Ebolavirus) infection.
Jean-Jacques Muyembe is a Congolese microbiologist. He is the general director of the Democratic Republic of the Congo Institut National pour la Recherche Biomedicale (INRB). He was part of team at the Yambuku Catholic Mission Hospital that investigated the first Ebola outbreak, and was part of the effort that discovered Ebola as a new disease, although his exact role is still subject to controversy. In 2016, he led the research that designed, along with other researchers at the INRB and the National Institute of Health Vaccine Research Center in the US, one of the most promising treatment for Ebola, mAb114. The treatment was successfully experimented during recent outbreaks in the DRC, on the express decision of the then DRC Minister of Health, Dr Oly Ilunga, despite a prior negative advice from the World Health Organization.
The Institut National de la Recherche Biomédicale (INRB) is the national medical research organization of the Democratic Republic of the Congo. The responsible ministry is the Ministry of Scientific Research and Technology.
The COVID-19 pandemic in the Democratic Republic of the Congo was a part of the worldwide pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2. The virus was confirmed to have reached the Democratic Republic of the Congo on 10 March 2020. The first few confirmed cases were all outside arrivals.
In August–November 1976, an outbreak of Ebola virus disease occurred in Zaire. The first recorded case was from Yambuku, a small village in Mongala District, 1,098 kilometres (682 mi) northeast of the capital city of Kinshasa.
Atoltivimab/maftivimab/odesivimab, sold under the brand name Inmazeb, is a fixed-dose combination of three monoclonal antibodies for the treatment of Zaire ebolavirus. It contains atoltivimab, maftivimab, and odesivimab-ebgn and was developed by Regeneron Pharmaceuticals.
Ibrahima Socé Fall is a Senegalese executive in the area of global health. He is Assistant Director-General for Emergencies Response at the World Health Organization (WHO) and United Nations Assistant – Secretary-General. Fall has worked on various outbreak response and research teams in the field to eradicate the spread of diseases including COVID-19, Ebola, malaria, AIDS, and tuberculosis. He was previously the Regional Emergencies Director of the WHO in the African Region and worked on Health Security and emergency preparedness and specially on emerging and re-emerging infectious diseases, epidemics and humanitarian crises.
On 7 February 2021, the Congolese health ministry announced that a new case of Ebola near Butembo, North Kivu had been detected the previous day. The case was a 42-year-old woman who had symptoms of Ebola in Biena on 1 February 2021. A few days after, she died in a hospital in Butembo. The WHO said that more than 70 people who had contact with the woman had been tracked.
Mpox is endemic in western and central Africa, with the overwhelming majority of cases occurring in the Democratic Republic of the Congo (DRC), where the more virulent clade Ib has seen a rapid rise in infections since September 2023.